149 results
Page 4 of 8
8-K
EX-99.1
wifdoha78v 6x2b
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
424B5
y5h82ffllggaqx8bnqic
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
wwnepf95
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
srrfzq
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
eqrrwl krog7vc
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
wq3lzr
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-10.1
zoov8gccrxmmcp 3yn
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
dd2mnhb w2x40tu
25 Jul 19
Other Events
8:07am
8-K
EX-99.1
fbo9f
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
vnk2o4c5
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am